COYA - CIK 0001835022
The table below shows Coya Therapeutics, Inc.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$10.74M | -$10.29M | -$11.19M | -$7.24M | -$3.90M |
| Capital expenditure | - | - | - | - | - |
| Investing cash flow | -$1.16M | -$25.00K | -$543.19K | -$525.00K | -$136.80K |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - | - |
Coya Therapeutics, Inc. reported operating cash flow of -$10.74M for fiscal year 2025. That is down 4.4% from -$10.29M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$3.90M (FY 2021) to -$10.74M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Financing cash flow | $20.39M | $16.03M | $38.43M | $9.36M | -$340.58K |